• Lumos Diagnostics receives A$709,837 R&D tax rebate
• Funds support ongoing innovation and product development
• Rebate linked to advancements in portable reader technology
• Platform enhances detection and integration capabilities

Lumos Diagnostics, a leader in rapid, point-of-care diagnostic technologies, announced it received a cash refund of A$709,837 related to its Research and Development Tax Incentive for FY25. The refund is mainly associated with ongoing research and development efforts focused on enhancing its proprietary portable handheld and disposable reader technology platforms. These platforms support the detection of a broader range of clinical biomarkers, improve the interpretation of point-of-care test results, and allow for smooth integration with electronic medical records. The funding assists with the evolution of the company's reader platform, a core component of its diagnostics offering.

Lumos remains committed to advancing point-of-care technologies that deliver meaningful clinical outcomes.